Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study
Rampersad, C., Kraut, E., Whitlock, R., Komenda, P., Woo, V., Rigatto, C., Tangri, N.
American Journal of Kidney Diseases
Sodium glucose cotransporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease and prevent heart failure events. However, SGLT2 inhibitors may increase the risk of acute kidney injury (AKI). Our objective was to assess whether SGLT2 inhibitor use, compared to all other glucose lowering drugs (oGLD), is associated with increased rates of AKI.